ProPhase Labs (NASDAQ:PRPH) Shares Pass Below 200 Day Moving Average – What’s Next?
ProPhase Labs (NASDAQ:PRPH) Stock Crosses Below 200 Day Moving Average – What’s Next?
ProPhase Labs Reports Year-End 2025 Results, Highlights Accelerating Settlement Activity and Investment-Ready Crown Medical Collections Platform
ProPhase Labs (NASDAQ:PRPH) Shares Pass Below 200 Day Moving Average – Time to Sell?
ProPhase Labs Provides Business Update Highlighting Advancing Crown Medical Collections Activity
ProPhase Labs Initiates Potential Sale or Strategic Partnership of BE-Smart™ and Advances Crown Medical Collections Initiative
ProPhase Labs Provides Crown Medical Collections Update; 250+ Insurance Payors Engaged, Approximately 50 Matters in Advanced Settlement Posture
ProPhase Labs (NASDAQ:PRPH) Stock Price Crosses Below Two Hundred Day Moving Average – Should You Sell?
ProPhase Labs (NASDAQ:PRPH) Shares Pass Below Two Hundred Day Moving Average – Time to Sell?
ProPhase Labs Provides Update on Convertible Debt Conversions, Capital Structure, and Underlying Asset Value
Head to Head Contrast: Hikma Pharmaceuticals (OTCMKTS:HKMPF) vs. ProPhase Labs (NASDAQ:PRPH)
ProPhase Labs Signs Non-Binding LOI for Proposed Reverse Merger with Advanced Biological Laboratories
ProPhase Labs (NASDAQ:PRPH) versus Grifols (NASDAQ:GRFS) Head to Head Survey
ProPhase Labs, Inc. (PRPH) Discusses Milestones in Cancer Diagnostics, Genomics Expansion, and COVID Accounts Receivable Collection Transcript
Join ProPhase Labs' Exclusive Live Investor Webinar and Q&A Session on December 1
ProPhase Labs, Inc. (PRPH) Q3 2025 Earnings Call Transcript
ProPhase Labs Reported Results for the Third Quarter Ended September 30, 2025, and Will Hold a Virtual Conference Call Today at 2pm ET.
ProPhase Labs, Inc. to Present Third Quarter 2025 Financial Results on November 19
ProPhase Labs Urges Shareholders to Vote by November 23 on Proxy Proposals
ProPhase Labs Announces Publication of BE-Smart Esophageal Cancer Study in the Official Journal of the American College of Gastroenterology
ProPhase Labs Engages RedChip Companies to Lead Investor Relations Efforts
ProPhase Labs to Present at the 2025 ThinkEquity Conference
ProPhase Labs Announces Study Validating BE-Smart Esophageal Cancer Test Accepted by Journal of Clinical Gastroenterology and Hepatology
PROPHASE LABS, INC. ANNOUNCES COMPLETION OF IMPORTANT NEXT STEP FOR CROWN MEDICAL COLLECTIONS $50 MILLION A/R INITIATIVE
ProPhase Continues its Exploration of a Crypto Treasury Strategy
ProPhase Labs Stockholders Approve All Proposals at September 9, 2025 Special Meeting By More Than 75% In Favor
ProPhase Labs Inc. to Participate in Renmark's Virtual Non-Deal Roadshow Series on Thursday, September 4, 2025
ProPhase Labs, Inc. (PRPH) Q2 2025 Earnings Call Transcript
ProPhase Labs Announces Filing of Definitive Proxy Statement and New Date for Special Meeting of Shareholders
ProPhase Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025
ProPhase Labs Announces Full USPTO Approval for Issuance of U.S. Patent Protecting Esophageal Adenocarcinoma Risk Assessment
ProPhase Labs Inc. to Present Second Quarter 2025 Financial Results on August 13, 2025
ProPhase Labs Announces Special Meeting of Shareholders and Filing of Preliminary Proxy Statement
ProPhase Labs Announces Closing of $3 Million Senior Secured Convertible Notes Financing
ProPhase Labs Board of Directors Authorizes Management to Explore Strategic Reverse Merger and Approves Crypto Treasury Initiative
ProPhase Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule
ProPhase Labs Announces Successful Study Demonstrating Performance of BE-Smart™ Test in Detecting Esophageal Cancer
52,394 Shares in ProPhase Labs, Inc. (NASDAQ:PRPH) Acquired by Squarepoint Ops LLC
ProPhase Labs Announces Formation of Clinical Science Advisory Board to Accelerate Commercialization of BE-SmartTM Esophageal Disease Diagnostic Platform
ProPhase Labs, Inc. (PRPH) Q1 2025 Earnings Call Transcript
ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2025
ProPhase Labs Inc. to Present First Quarter 2025 Financial Results on May 20, 2025
ProPhase Labs, Inc. (PRPH) Q4 2024 Earnings Call Transcript
ProPhase Labs, Inc. Announces Financial Results for the Year Ended December 31, 2024
ProPhase Labs Inc. to Present 2024 Year End Financial Results on March 31, 2025
ProPhase Labs to Present at the Investor Summit Virtual on March 11
Bears are Losing Control Over ProPhase Labs (PRPH), Here's Why It's a 'Buy' Now
Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)
ProPhase Labs Examines Strategic Opportunities to Leverage Its DTC Multi-Media Infrastructure with Telehealth Physician Networks for Prescription Drugs
ProPhase Labs Announces Excellent Progress with Crown Medical Collections Targeting Over $50 Million in Net Near-Term Cash Recovery from COVID-19 Receivables